Gene · 2921
NIH grants2,607
NIH grants whose papers are about the gene, through NIH's grant-paper links.
1,021 to 1,040 of 2,607
Download this page as JSON| Grant | Title | CXCL3 papers | Newest fiscal year |
|---|---|---|---|
| R01AI127864 | NFkB Signaling in Macrophages | 1 | 2021 |
| R01AI130131 | Kruppel-Like Factor 2 Counters Vascular and Immunologic Dysfunction in Child Cerebral Malaria | 1 | 2021 |
| R01AI132835 | Coordinated dynamic regulation and function of IRF transcription factors | 1 | 2021 |
| R01AI132963 | Novel humanized mouse model developed from cord blood CD34 positive HSC and autologous iPS cell derived thymus | 1 | 2021 |
| R01AI133351 | Novel antimicrobial agents to overcome antibiotic resistant Pseudomonas and MRSA respiratory infection | 1 | 2021 |
| R01AI133977 | Alternatively activated macrophages during helminth infection | 1 | 2021 |
| R01AR070864 | Evaluating the Potential of Human Induced Pluripotent Stem Cells (hiPSC) For Cartilage Repair | 1 | 2021 |
| R01AT009562 | Discovery of GPCR-active natural products and their biosynthetic genes from the human associated bacteria | 1 | 2021 |
| R01AT009708 | Identification and characterization of gut microbial bioactive molecules that determine predisposition to autoimmune disease and atopy | 1 | 2021 |
| R01CA160331 | Chromatin basis of cellular senescence and its implication in epithelial ovarian cancer | 1 | 2021 |
| R01CA163377 | Targeting EZH2 in CARM1-expressing epithelial ovarian cancer | 1 | 2021 |
| R01CA204028 | The CXCR3 Chemokine System in Cancer Immunotherapy | 1 | 2021 |
| R01CA204806 | Consequences and mechanism of aberrant splicing in African American prostate cancer disparities | 1 | 2021 |
| R01CA205043 | Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer | 1 | 2021 |
| R01CA206890 | Imaging tumor associated macrophage (TAM) function | 1 | 2021 |
| R01CA210637 | Role of PD2/Paf1 in Pancreatic Acinar to Ductal Metaplasia | 1 | 2021 |
| R01CA212403 | Role and targeting of PRMT5 in prostate cancer | 1 | 2021 |
| R01CA213275 | KSHV microRNAs in tumor invasion and angiogenesis | 1 | 2021 |
| R01CA213278 | Reprogramming Tumor Microenvironment by Nanoparticle | 1 | 2021 |
| R01CA213987 | Safer Approaches to CRC Chemoprevention | 1 | 2021 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2921/grants?page=52